Key result
Serial ECG monitoring and electrolyte optimization manage heterogeneous QTc prolongation risk from targeted cancer therapies.
Why the study?
QTc prolongation is a major safety concern in oncology, where an expanding array of repolarization-altering cancer therapies overlaps with supportive drugs, electrolyte disturbances, and organ dysfunction. The risk of potentially lethal torsade de pointes must be balanced against the survival benefit of effective cancer therapy.
Drug-induced QT prolongation in oncology can be effectively managed without compromising cancer therapy through baseline and serial ECG monitoring, electrolyte optimization, multidisciplinary medication review, and emerging precision-medicine risk stratification tools.
IntroductionProlongation of the heart-rate-corrected QT interval (QTc) is a defining safety concern in oncology, where patients face an expanding array of repolarization-altering agents superimposed on supportive drugs, electrolyte disturbgances, and organ dysfunction. The anchoring event, torsade de pointes, is uncommon but potentially lethal, and arrhythmic risk must be balanced against the survival benefit of effective cancer therapy.MethodsThe literature was identified through structured searches of PubMed, Scopus, and Web of Science covering the mechanistic, drug-class, pharmacovigilance, pharmacogenomic, risk-prediction, and management aspects of drug-induced QT prolongation in oncology, and was synthesized narratively with an emphasis on precision-medicine dimensions.ResultsQT liability is heterogeneous across tyrosine kinase inhibitors, cyclin-dependent kinase 4/6 inhibitors, antibody-drug conjugates, arsenic trioxide, and supportive agents such as antiemetics, antifungals, opioids, and antibiotics, and is frequently amplified by electrolyte derangement and drug-drug interactions. Genetic susceptibility, real-world pharmacovigilance, and machine-learning risk prediction are emerging but remain underdeveloped in oncology. Pragmatic management rests on baseline and serial Fridericia-corrected electrocardiography, electrolyte optimization, judicious agent selection and dose modification, medication review within a multidisciplinary team, and selection of structured lower-risk alternatives.ConclusionsDrug-induced QT prolongation in oncology is manageable rather than inevitable. Combining genomic susceptibility, pharmacovigilance, and validated prediction tools offers a route to individualized risk stratification, although prospective oncology-specific evidence and data from under-represented populations remain limited. Early identification and disciplined monitoring allow clinicians to protect the heart without compromising effective cancer treatment.
No takes yet. Share an insight, caveat, or question.
Abdullah A Assiri (2026) conducted a review in Drug-induced QT prolongation in oncology. Oncology and supportive agents (TKIs, CDK4/6 inhibitors, ADCs, arsenic trioxide, antiemetics, antifungals, opioids, antibiotics) was evaluated on Heart-rate-corrected QT interval (QTc) prolongation and torsade de pointes. Oncology therapies including TKIs and CDK4/6 inhibitors carry heterogeneous QTc prolongation risk, which is manageable via serial Fridericia ECG monitoring and electrolyte optimization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: